Allergy Shots at Home? A 23,614-Patient Study Is Getting a Second Look

NEW YORK - Aug. 18, 2026 - For millions of Americans with seasonal or year-round allergies, allergy shots can offer something antihistamines and nasal sprays generally cannot: the possibility of changing the underlying allergic response over time. Subcutaneous immunotherapy (SCIT), commonly called allergy shots, remains one of the best-studied disease-modifying treatments for allergic rhinitis, allergic asthma, and related conditions. Yet its practical demands have long limited access and adherence.

Traditional allergy shots usually require repeated visits to a medical office. Patients often go once or twice a week during the early build-up phase, then continue with regular maintenance injections for three to five years. The American Academy of Allergy, Asthma & Immunology (AAAAI) generally recommends that these injections be given in a medical setting because, while uncommon, systemic reactions and anaphylaxis can occur. Most reactions develop within 30 minutes of an injection, which is why conventional practices ask patients to stay for observation afterward.

But what if carefully selected patients could administer those injections themselves at home? That idea has been studied more carefully than many people realize-and it sits alongside a related option that has already become widely accepted for home use: sublingual immunotherapy [https://getcurex.com/] (SLIT), also known as allergy drops or allergy tablets.

The Large Home-SCIT Safety Study

Researchers examined a home-based allergy-shot protocol developed by United Allergy Services [https://unitedallergyservices.com/] and published findings in a 2015 study of 23,614 patients [https://pubmed.ncbi.nlm.nih.gov/25476041/] who self-administered more than 2 million injections over a one-year period. They reported 37 systemic reactions, or about 0.16% of patients and 0.002% of injections. Nine of those reactions occurred in pediatric patients and 28 in adults. No fatalities were reported. A broader look at the same protocol from 2009 through early 2014 found more than 90,000 patients receiving over 10 million injections without fatalities.

The key was not simply mailing allergy shots home. It was changing how patients were selected, trained, and dosed. United Allergy Services used what it calls a "low and slow" approach. Higher-risk patients were excluded, and doses were increased more gradually than in many conventional schedules. The protocol also required patients to have epinephrine available and another trained adult present during injections-an "immunotherapy partner" who knew how to recognize and respond to a reaction.

Those precautions matter. The main concern with allergy shots is anaphylaxis. Serious reactions are uncommon, but they can develop quickly. By preselecting lower-risk patients and slowing the build-up phase, the reported systemic-reaction rate in this large cohort was substantially lower than rates often cited for traditional office-based SCIT (commonly in the 3-14% range in earlier literature).

This study should not be read as proof that allergy shots are safe for unsupervised home use by everyone. Instead, it raises a more interesting question: Can careful patient selection, gradual dosing, education, emergency preparedness, and ongoing physician oversight allow certain lower-risk patients to receive treatment outside a traditional allergy office?

Important Limitations and Context

There are important limitations. The analysis looked at patients treated under one specific protocol rather than a randomized trial comparing home versus office injections head-to-head. Several authors had ties to United Allergy Services, which were disclosed in the paper. And mainstream guidance remains cautious-AAAAI still considers an allergist's office the preferred location for allergy shots.

These caveats are especially relevant when comparing SCIT with sublingual immunotherapy. SLIT has a different risk profile. Systemic reactions with allergy drops or tablets are generally less frequent and less severe than with shots, which is one reason SLIT has long been considered suitable for home administration after an initial supervised dose. Local reactions (itching or mild swelling under the tongue or in the mouth) are more common with SLIT, but serious systemic events remain rare when products are used as directed.

The Rise of At-Home Options and Telemedicine

Now the home-treatment concept is entering the telemedicine era. Curex, one of the larger online allergy-care providers in the U.S., has built its model primarily around at-home sublingual immunotherapy-personalized allergy drops prescribed by clinicians and shipped directly to patients. The company has also moved into at-home SCIT options that draw on approaches similar to the United Allergy Services protocol. Patients can complete evaluation, testing coordination, and ongoing monitoring largely through telemedicine, with customized extracts delivered to the home.

The combination could help solve one of SCIT's biggest practical problems: convenience. A multi-year treatment becomes much harder to stick with when every dose requires commuting to a clinic, scheduling around office hours, and waiting after each injection. Adherence rates for traditional allergy shots are often disappointing; many patients discontinue before completing the recommended course. Home options-whether carefully supervised SCIT or the more established daily sublingual immunotherapy regimen-remove many of those logistical barriers.

Sublingual immunotherapy offers distinct advantages for many patients seeking at-home care. Drops or tablets are taken daily under the tongue, require no needles, and carry a favorable safety profile for home use after the first dose is given under medical observation. Evidence supports SLIT's ability to reduce symptoms of allergic rhinitis and, in some cases, improve quality of life and decrease medication use. While the depth of randomized-trial data is strongest for certain standardized SLIT tablets (grass, ragweed, dust mite), compounded drops used by many telemedicine practices allow multiallergen customization that matches how many U.S. patients are treated with SCIT.

Telemedicine cannot remove the medical risks of allergy shots. But it may make it possible to build stronger screening, education, monitoring, and follow-up around a home-based SCIT protocol that existed long before virtual allergy clinics became common. The same digital infrastructure that supports high-touch at-home sublingual immunotherapy programs-remote check-ins, symptom tracking, rapid clinician access, and clear emergency protocols-can also strengthen oversight for selected patients on home injections.

Weighing SCIT and SLIT for Home Treatment

For patients considering disease-modifying therapy, the choice often comes down to individual factors: number and severity of allergies, preference for injections versus daily drops, insurance coverage, risk tolerance, and ability to follow safety protocols. Traditional office-based SCIT still offers the longest track record and the strongest evidence base for certain severe or complex cases. Sublingual immunotherapy provides a needle-free, highly convenient alternative that is already routinely administered at home. Carefully selected home SCIT aims for a middle ground-preserving the higher cumulative dosing potential of shots while addressing the access and adherence problems that have limited their reach.

Both approaches require medical supervision, proper patient education, availability of epinephrine where indicated, and ongoing follow-up. Neither is appropriate for every patient. Uncontrolled asthma, a history of severe reactions, certain medical conditions, or inability to recognize and respond to early signs of a systemic reaction are reasons clinicians exclude candidates from home administration of either modality.

Looking Ahead

For many allergy sufferers, these evolving models offer an intriguing middle ground-preserving the disease-modifying potential of traditional allergy immunotherapy while rethinking where, and for carefully selected patients, how treatment has to be given. The open question now is whether larger prospective studies will confirm that home SCIT stays safe and effective when scaled through modern telemedicine, and how real-world outcomes for sublingual immunotherapy delivered entirely via telehealth continue to compare with clinic-based care.

As more data accumulate and digital tools improve monitoring, the boundary between "office only" and "home possible" is likely to keep shifting. Patients who once faced years of weekly clinic visits may increasingly have viable options that fit real life-provided selection remains rigorous, education is thorough, and physicians retain meaningful oversight. Allergy shots at home will never be appropriate for everyone, but for the right patients under the right protocol, the large observational evidence already available suggests the concept is worth continued, careful evaluation alongside the more established home use of sublingual immunotherapy.

About Curex, Inc.

Curex, Inc. is a U.S.-based online allergy-care provider offering telemedicine-supported allergy treatment options. The company focuses primarily on at-home sublingual immunotherapy and provides patients with clinician-guided allergy care through a digital platform. Curex also offers at-home SCIT options for eligible patients under medical supervision.

Media Contact
Company Name: Curex, Inc.
Contact Person: Media Relations
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergy-shots-at-home-a-23614patient-study-is-getting-a-second-look]
Country: United States
Website: https://getcurex.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.